DARZALEX® (daratumumab) Subcutaneous Formulation-Based globenewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from globenewswire.com Daily Mail and Mail on Sunday newspapers.
Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces that the first patient has been dosed in a United States (U.S.) expanded access program (EAP, ClinicalTrials.gov ID: NCT06090331) for TLX250-CDx (89Zr-DFO-girentuximab). TLX250-CDx is the Company's first-in-class, non-invasive investigational positron emission tomography (PET) imaging agent in clear cell renal cell carcinoma (ccRCC).
Jon Bloom, MD, CEO and Co-founder of Podimetrics Sukanya Soderland, SVP, Chief Strategy Officer at Blue Cross Blue Shield of Massachusetts During Diabetes Awareness month (November) - and every month - someone is having a
First Patient Dosed in U S Expanded Access Program for TLX250-CDx, Telix s Breakthrough Kidney Cancer Imaging Agent fnarena.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from fnarena.com Daily Mail and Mail on Sunday newspapers.
Amylyx Pharmaceuticals, Inc. today announced the publication of analyses performed on neuroinflammatory biomarkers using plasma samples from participants with amyotrophic lateral sclerosis from.